Twist Bioscience Corporation (NASDAQ:TWST) Receives $44.67 Consensus Target Price from Brokerages

Twist Bioscience Corporation (NASDAQ:TWST) has earned an average rating of “Moderate Buy” from the ten brokerages that are covering the firm, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a sell recommendation and eight have given a buy recommendation to the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $44.6667.

A number of brokerages have recently issued reports on TWST. Weiss Ratings reissued a “sell (d-)” rating on shares of Twist Bioscience in a research report on Monday, December 29th. Barclays lifted their price objective on shares of Twist Bioscience from $37.00 to $39.00 and gave the company an “overweight” rating in a research report on Monday, December 15th. Stephens initiated coverage on Twist Bioscience in a research report on Monday, November 3rd. They issued an “overweight” rating and a $41.00 target price on the stock. Evercore ISI reiterated an “outperform” rating and set a $42.00 price objective on shares of Twist Bioscience in a research report on Monday, January 5th. Finally, TD Cowen reiterated a “buy” rating on shares of Twist Bioscience in a research report on Thursday, January 8th.

Twist Bioscience Price Performance

NASDAQ TWST opened at $45.15 on Friday. The stock has a market capitalization of $2.77 billion, a price-to-earnings ratio of -34.47 and a beta of 2.19. Twist Bioscience has a 1-year low of $23.30 and a 1-year high of $55.33. The company has a debt-to-equity ratio of 0.03, a current ratio of 3.64 and a quick ratio of 3.33. The business’s fifty day moving average price is $33.38 and its 200-day moving average price is $31.45.

Twist Bioscience (NASDAQ:TWST) last posted its quarterly earnings data on Friday, November 14th. The company reported ($0.45) EPS for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.05). Twist Bioscience had a negative net margin of 20.63% and a negative return on equity of 27.40%. The firm had revenue of $99.01 million for the quarter, compared to analysts’ expectations of $97.40 million. On average, equities analysts predict that Twist Bioscience will post -2.12 earnings per share for the current year.

Insider Buying and Selling at Twist Bioscience

In other news, CAO Robert F. Werner sold 1,016 shares of the business’s stock in a transaction on Thursday, October 30th. The shares were sold at an average price of $31.44, for a total transaction of $31,943.04. Following the completion of the sale, the chief accounting officer directly owned 51,030 shares of the company’s stock, valued at approximately $1,604,383.20. The trade was a 1.95% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Dennis Cho sold 1,019 shares of the company’s stock in a transaction dated Monday, November 3rd. The stock was sold at an average price of $32.08, for a total transaction of $32,689.52. Following the completion of the transaction, the insider owned 120,694 shares in the company, valued at $3,871,863.52. This represents a 0.84% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 66,437 shares of company stock valued at $2,136,365. 3.08% of the stock is owned by company insiders.

Hedge Funds Weigh In On Twist Bioscience

Large investors have recently bought and sold shares of the business. SteelPeak Wealth LLC lifted its stake in shares of Twist Bioscience by 14.0% during the 4th quarter. SteelPeak Wealth LLC now owns 20,868 shares of the company’s stock worth $662,000 after purchasing an additional 2,570 shares during the last quarter. SG Americas Securities LLC raised its holdings in shares of Twist Bioscience by 350.3% in the fourth quarter. SG Americas Securities LLC now owns 76,484 shares of the company’s stock worth $2,426,000 after buying an additional 59,500 shares during the last quarter. Tudor Investment Corp ET AL acquired a new stake in Twist Bioscience during the 3rd quarter worth about $717,000. CIBC Bancorp USA Inc. acquired a new stake in shares of Twist Bioscience during the third quarter worth about $685,000. Finally, Jacobs Levy Equity Management Inc. boosted its holdings in shares of Twist Bioscience by 37.3% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 497,138 shares of the company’s stock valued at $13,989,000 after acquiring an additional 134,929 shares during the last quarter.

About Twist Bioscience

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.